Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III comparison of Gan & Lee insulin glargine versus Lantus in type 2 diabetes mellitus
2017-001415-36Phase 3Terminated
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Dec 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Gan & Lee Pharmaceuticals. Primary endpoint: Change in HbA1c from baseline at Week 26. Started Dec 2017; status: terminated.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2017-001415-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001415-36.